10x Genomics acquires ReadCoor, Inc.

10x Genomics acquired ReadCoor, Inc. for $407.4 million, a transaction completed in October 2020, structured as Cash-and-stock merger; total consideration $407.4M comprising $101.4M cash and $306.0M in stock (1,901,382 Class A shares, contractual value $250M). Announced headline of $350M cash and stock..

ReadCoor, Inc. operates in In Situ Analysis, is based in Cambridge, Massachusetts, United States. Acquisition of Cambridge, MA-based ReadCoor, Inc., a developer of foundational In Situ RNA analysis technology spun out of George Church's lab at Harvard. Announced October 5, 2020 for cash and stock consideration of $350 million and completed October 13, 2020.

Acquire comprehensive and foundational In Situ IP, key technology advances and deep talent to extend the product roadmap and establish a third technology platform alongside Chromium and Visium.

In Situ IP, technology and talent combined with internal innovation to form the foundation of the Xenium platform; over 110 combined In Situ patents added to 10x's portfolio. In Situ Analysis / Xenium platform

We believe that In Situ approaches will be essential for how biological research and clinical assays will be conducted in the future. After a comprehensive assessment of In Situ efforts worldwide, we are thrilled to welcome ReadCoor and CartaNA to the 10x team.Serge Saxonov, co-founder and CEO of 10x Genomics

We have followed and been impressed with 10x Genomics for years and look forward to combining forces as we execute on a shared vision.Richard Terry, founder and CEO of ReadCoor

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.